Product details
Background：Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer.
• AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications., PMID:31684958
• The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion., PMID:34244439
• GAS6 attenuates sepsis-induced cardiac dysfunction through NLRP3 inflammasome-dependent mechanism., PMID:37979891
• Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily., PMID:17064312
• Growth arrest-specific protein-6/AXL signaling induces preeclampsia in rats†., PMID:31347670
• Growth arrest-specific protein 6 (Gas6) attenuates inflammatory injury and apoptosis in iodine-induced NOD.H-2h4 mice., PMID:31129420
• A review on the role of GAS6 and GAS6-AS1 in the carcinogenesis., PMID:34481213
• Growth arrest-specific protein 6 (Gas6) as a noninvasive biomarker for early detection of diabetic nephropathy., PMID:28513288
• Gas6-Axl signal promotes indoor VOCs exposure-induced pulmonary fibrosis via pulmonary microvascular endothelial cells-fibroblasts cross-talk., PMID:38824778
• Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma., PMID:35760058
